Original Research Article

Study of QT interval prolongation in asymptomatic type-2 diabetes mellitus patients with and without microalbuminuria

Farzana Mustafa1*, Abdul Hai Mohammed2

1 Dept. of physiology, Malla Reddy Institute of Medical Sciences, Telangana, Hyderabad, India
2 Deccan College of Medical Sciences, Hyderabad, Telangana, India

ABSTRACT

QT interval abnormalities are the best predictors of cardiovascular deaths. Microalbuminuria is an independent marker for cardiovascular disease in diabetes mellitus. Hence QT interval abnormalities in diabetics with or without microalbuminuria were evaluated in this study.

Objective: To study QT interval abnormalities in asymptomatic type 2 diabetic patients with or without microalbuminuria.

Material and Methods: Open label controlled study with 214 subjects of either sex. Group A healthy subjects (n=100), group B asymptomatic, type 2 diabetics with no clinical evidence of cardiac disease. Group B subdivided into B1 with microalbuminuria (n=62), B2 without microalbuminuria (n=52). Corrected QT interval (QTC), microalbuminuria, and blood pressure were measured for all subjects. QTC was calculated by using Bazzet’s formula. QTC more than 440msec was considered prolonged.

Results: QTC was within normal range in diabetic patients (415±25msec). Highly significant (p<0.0001) prolongation was observed in diabetics, compared to healthy subjects. Both B1 (p<0.0001) and B2 (p<0.001) groups showed a significant increase in QTC than in healthy subjects. Among B1 and B2 groups QTC was not statistically significant.

Conclusion: Prolongation of QTC is indicative of CAN. CAN is often under-recognised and undiagnosed cardiac complication. QTC was more in asymptomatic type 2 diabetics irrespective of microalbuminuria compared to healthy individuals, though values were within normal range. This denotes high risk for future cardiovascular complications in diabetic patients.

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

Epidemiological data shows alarming values that predict a worrisome projected future for T2DM. According to the International Diabetes Federation1 (IDF) in 2019 diabetes caused 4.2 million deaths; and 463 million adults aged between 20 and 79 years old were living with diabetes, a number that will likely rise up to 700 million by 2045. Diabetes was the underlying cause of at least 720 billion USD in health expenditure in 2019. Ninety percent of Diabetic patients have type 2 Diabetes mellitus and it has emerged as one of the 21st’ century’s health problems.2,3

The true disease burden of T2DM is likely an under representation as 1 in 3 diabetic people were under diagnosed, equivalent to 232 million people. The greatest number of people suffering from diabetes are aged between 40 and 59 years old. Incidence and prevalence of T2DM vary according to geographical region, with more than 80% of patients living in low to-middle-income countries, which poses additional challenges in effective treatment. Patients with T2DM have a 15% increased risk of all-cause mortality compared with people without diabetes with cardiovascular...
Type 2 Diabetes Mellitus (T2DM) is one of the most common metabolic disorders world wide. Over 90% of diabetes mellitus cases are T2DM, a condition marked by deficient insulin secretion by pancreatic islet β-cells, tissue insulin resistance (IR) and an inadequate compensatory insulin secretory response. Diabetes mellitus may lead to complications affecting many organ systems. The microvascular complications are retinopathy, nephropathy and neuropathy. The macrovascular complications are coronary artery disease, peripheral arterial disease and cerebrovascular disease. Nonvascular complications are gastroparesis, infections and skin changes. Jake Rajbhandari et al. Diabetic heart disease: A clinical update

World J Diabetes. 2021 mentions that diabetic heart disease is a conglomeration of coronary artery disease (CAD), cardiac autonomic neuropathy (CAN), and diabetic cardiomyopathy (DCM). Higher prevalence at a lower age and more aggressive disease in DM-associated CAD make diabetic individuals more vulnerable to premature death.

The main cause of death and morbidity in patients with diabetes is vascular complications. Diabetes is a known cardiovascular risk factor and there is a necessity to identify the factors that may improve cardiovascular risk in diabetic patients by using non-invasive and low cost approaches (Giunti et al. 2012). One possible way to risk stratification in diabetic patients, is to use QT interval analysis, QT interval (QTC) prolongation is linked to microalbuminuria in patients with type 2 diabetes and to investigate their association by comparing with healthy individuals.

Our hypothesis was that asymptomatic Type -2 diabetic patients with microalbuminuria had cardiac involvement that might be subclinical, as reflected by more prolonged QTC, as compared to those without microalbuminuria and healthy controls.

2. Materials and Methods

It was an open label controlled study with a total of 214 subjects of either sex. The present study was conducted in Gandhi Medical College, Hyderabad, India, after approved by Institutional Ethics Committee and obtaining informed consent. Inclusion criteria were asymptomatic type 2 diabetic patients with no clinical evidence of cardiac disease, no H/O chest pain or shortness of breath, no H/O cardiac procedures, age between 30-70 years. Exclusion criteria were H/O coronary heart disease, H/O chest pain or shortness of breath, ECG abnormalities, patients with hepatic and renal abnormalities, type 1 diabetes mellitus, patients taking drugs, which affects the QT interval. And patients with abnormal levels of serum Potassium and Calcium were excluded.

The study subjects were divided into 1) Group A — Healthy controls (n=100) 2) Group B — Asymptomatic, type 2 diabetic patients. Group B was again subdivided into 2 groups. Group B 1 diabetic patients with microalbuminuria (n=62), Group B2 diabetic patients without microalbuminuria (n=52). All participants were subjected to detailed history and physical examination, Blood pressure was recorded. Biochemical tests, fasting blood sugar levels (FBS), post-prandial blood sugar (PPBS). Blood pressure was recorded. Biochemical tests, fasting blood sugar levels (FBS), post-prandial blood sugar (PPBS). Serum potassium, calcium and urine for microalbuminuria were done ECG was taken and QT interval and corrected QT interval (QTC) were calculated. ECG abnormalities were registered according to Minnesota code.

QT interval was measured manually in chest leads V3, V4, V5, V6 and limb leads I,II.

Leads with the longest QT interval was taken since QT interval is affected by heart rate. The interval between two successive R-R waves was calculated and corrected QT (QTC) interval was calculated using Bazett's formula (Bazett. 1920)

\[
QTC = \frac{QT \text{ interval}}{\sqrt{R-R \text{ interval(msec)}}}
\]

Value of QTC interval exceeding 440 msec was taken as prolonged.

For measuring microalbuminuria early morning or spot urine samples were used. Urine was tested using routine dip sticks for RBC, leukocytes and protein. If urine was negative for above, then a sample was sent for microalbuminuria estimation.

Specimen was analyzed as soon as possible after the collection, as the storage time and temperature may affect the albumin levels in the urine.
Urine albumin levels were measured by immunoturbidimetric method and concentration more than 20 mg/L was taken as positive. The normal microalbuminuria value is less than 20 mg/L. The value greater than 20 mg/L was taken as positive for microalbuminuria. 14

2.1. Statistical analysis

All values were expressed as mean±standard deviation (SD).

Analysis of Variance, (ANOVA) was applied to compare the data between the two groups Unpaired ‘t’ test was used to calculate p value. P<0.05 was considered statistically significant.

3. Results

A total of 214 subjects of either sex were evaluated in the study. Out of which 100 were healthy subjects and 114 were asymptomatic type-2 diabetic patients. In Group A, 60 were males and 40 were females. Age in Group A was 49±9.4 years, in Group B was 53±10 years.

Microalbuminuria in healthy subjects was 8.8±3.8 mg/dl and in diabetics, it was 32.4±54 mg/dl showing highly significant (p<0.0001) increase in diabetic patients (Table 1).

Microalbuminuria within the diabetic groups, B1 was 49±69 mg/dl and in Group B was.

12.6±6.5 mg/dl There was highly significant (p<0.001) increase in microalbuminuria in Group B1 compared to Group B2 (Table 1). Both the diabetic groups B1 and B2 showed significant increase in microalbuminuria which was p<0.0001 and p=0.001 respectively, compared to healthy controls. (Table 1)

QTC interval in healthy subjects was 388±21 msec and in Group B diabetic patients, it was 415±25 msec which showed highly significant (p<0.0001) increase in QTC interval when compared to Group A healthy controls (Table 1), though they were within the normal range.

In Group B1, diabetic patients with microalbuminuria, QTC interval was 419±22 msec, and in Group B2 diabetics without microalbuminuria it was 411±28 msec.

Both B1 and B2 groups showed highly significant increase in QTC interval, which was significant p<0.0001 and p<0.001 respectively, compared to healthy controls. (Table 1)

In between B1 and B2 QTC interval was found to be statistically insignificant. (Table 1)

The mean systolic blood pressure (SBP) in healthy subjects was 120±9.0 mm of Hg and in diabetic patients it was 132±18 mm of Hg. There was highly significant(p<0.0001) increase in mean SBP in diabetic patients, compared to healthy controls.

Mean diastolic blood pressure (DBP) in healthy subjects was 74±8.0 mm of Hg and in diabetic patient it was 79±11 mm of Hg, showing highly significant increase in diabetics than the healthy subjects. In groups B1 and B2 they did not show any significant difference in both SBP and DBP (Table 1).

Fasting blood sugar (FBS) in healthy subjects was 79±9.0 mg/dl whereas in diabetic group it was 126±45 mg/dl, there was highly significant increase in FBS within the diabetic patients compared to the control group. FBS within the diabetic groups B1 and B2 was not statistically significant (Table 1).

Postprandial blood sugar (PPBS) in healthy subjects was 132±12 mg/dl whereas in diabetic group B was 187±73 mg/dl showing highly significant increase in PPBS in diabetic patients compared to healthy subjects. Within the diabetic groups B1 and B2 PPBS was not statistically significant.

There was no statistically significant difference in serum potassium and serum calcium levels between diabetic patients and healthy controls (Table 1).

4. Discussion

In the present study we have observed that microalbuminuria was significantly increased in asymptomatic type 2 diabetes mellitus patients, with no clinical evidence of coronary heart disease, compared to healthy controls. Similar to our findings there are several studies which have demonstrated to have significant microalbuminuria in type 2 diabetic patient. 15

Presence of microalbuminuria in patients with Type 2 DM was a predictor of clinical proteinuria and increased mortality. It is a strong independent risk factor for cardiovascular disease in diabetic and non-diabetic individuals and may be a useful marker for diffuse endothelial dysfunction. 15

Microalbuminuria may also be strongly related to confounding factors like hyperglycemia, hypertension, insulin resistance or atherosclerotic disease.

The sensitivity, specificity and positive predictive value of QTc prolongation for the diagnosis of CAN were 76.5%, 75% and 81.3% in type 2 diabetes. 16 Higher CAN scores correlated with longer QTc intervals. 16

Our study showed that QTc prolongation in type 2 diabetes mellitus patients was significantly higher when compared to healthy controls, though they were within the normal range. Similar to our results Takebayashi et al. observed that type 2 patients had greater QTc prolongation than healthy controls 17 (Takebayashi et al. 2003). With regard to type 2 DM, two studies have shown that QT interval abnormalities are particularly good predictors of cardiac death 8,9 (Naas et al 1998, Sawick et al 1996). In the previous studies (Porwal et al. 2005, Vegilo et al. 2002) it was observed that QT interval was increased above normal
Table 1: Characteristics of study subjects

| S. No. | Parameters                  | Group A [n=100] Mean±SD | Group B [n=114] Mean±SD | P Value | Group B1 [n=62] Mean±SD | Group B2 [n=52] Mean±SD | P value |
|-------|-----------------------------|-------------------------|-------------------------|---------|-------------------------|-------------------------|---------|
| 1     | SBP (mm of Hg)              | 120±9.0                 | 132±18                  | <0.0001 | 133.5±18.3              | 130±18.7                | NS      |
| 2     | DBP (mm of Hg)              | 74±8.0                  | 79±11                   | <0.0001 | 78.2±11.5               | 80.1±10                 | NS      |
| 3     | FBS (mg/dl)                 | 79±9.0                  | 126±45                  | <0.0001 | 128±53.1                | 122±32.1                | NS      |
| 4     | PPBS (mg/dl)                | 132±12                  | 187±73                  | <0.0001 | 195±84.4                | 177.6±58.3              | NS      |
| 5     | Serum K+ mmol/L             | 4.4±0.7                 | 4.3±0.7                 | NS      | 4.3±0.7                 | 4.2±0.5                 | NS      |
| 6     | Serum Ca+2 mg/dl            | 10.0±0.9                | 10.1±0.9                | NS      | 10.1±0.9                | 10.3±0.6                | NS      |
| 7     | Microalbumin in urine (mg/L)| 8.8±3.8                 | 32.4±5.4                | <0.0001 | 49±69                   | 12.6±6.5                | <0.0001 |
| 8     | QTC interval (msec)         | 388±21                  | 415±25                  | <0.0001 | 419±22                  | 411±28                  | NS      |

Group A: Healthy subjects, Group B- Diabetics, Group B1 Diabetics with microalbuminuria. Group B2: Diabetics without microalbuminuria.

SBP: Systolic blood pressure; DBP -Diastolic blood pressure, FBS- Fasting blood sugar; PPBS- Post prandial blood sugar; QTC is corrected QT interval

In our study we have observed that mean systolic and diastolic blood pressures were significantly higher in diabetic patients, compared to healthy subjects. Our results were consistent with the previous studies18,21 (Portwal et al. 2005, Vegilo et al. 2002, Sallas et al. 2006) which reported that diabetic patients tend to have high blood pressure and higher cardiovascular complications which affect QT interval more than healthy individuals.

Similar to previous studies we observed QTC was prolonged >440 msec in 29% of diabetic patients with or without microalbuminuria in our study.

No subjects had QTC prolongation of >440 msec in the control group.

Previous studies demonstrated significant increase of QTC interval in type 2 diabetes mellitus patients with microalbuminuria, when compared to normoalbuminuric diabetic patients,11,20 (Rutter et al.2002, Yeo et al. 2004).

However we found no statistically significant difference in QTC interval within the diabetic patients with or without microalbuminuria. This is because linear regression analysis showed that QT prolongation was not strongly linked to albumin excretion rate but more strongly to factors associated with microalbuminuria such as blood pressure and factor XIa11 (Rutter et al.2002). In our study, diabetic patients had significantly higher microalbuminuria than healthy controls. This might suggest that the microalbuminuria in diabetic patients without overt coronary heart disease could be an early indicator of cardiovascular autonomic neuropathy20 (Yeo et al.2004).

QTC abnormalities can occur independently of autonomic dysfunction or myocardial ischemia and may be related to the process which increases urinary albumin leakage and QT prolongation may contribute to increased mortality observed in microalbuminuria; subjects with type 2 diabetes mellitus11 (Rutter et al. 2002). QTC interval is an independent marker for coronary heart disease and is a predictor of sudden cardiac death.8

In our study we have observed that mean systolic and diastolic blood pressures were significantly higher in diabetic patients, compared to healthy subjects. Our results were consistent with the previous studies18,21 (Portwal et al. 2005, Vegilo et al. 2002, Sallas et al. 2006) which reported that diabetic patients tend to have high blood pressure and higher cardiovascular complications which affect QT interval more than healthy individuals.

Another study demonstrated that diabetic patients with microalbuminuria had higher mean systolic and diastolic pressures recorded over a 24 hour period, than normoalbuminuric diabetic patients.22 In our study, there was no significant difference in mean systolic and diastolic blood pressures between microalbuminuric and normoalbuminuric type 2 diabetic patients, as we have not recorded blood pressure over 24 hour period. However, presence of microalbuminuria that reflects renal involvement in diabetic patients, has been reported as a major determinant of ambulatory blood pressure.20

Microalbuminuria has been found independently predictive of mortality in clinical studies in Type-2 diabetic patients.20 Presence of Subclinical autonomic neuropathy is an important determinant of mortality in Type-2 diabetic patients by causing cardiac arrest.(Wirta et al.1997).

Microalbuminuria is an independent risk factor for cardiovascular and renal out- come in a patient with Type 2 diabetes. The evidence that intensive glycemic control reduces the microvascular complications of diabetes is based almost exclusively on prevention of micro- albuminuria.22 (Peter P. Swoboda et, al 2017) Asymptomatic diabetes mellitus patients with persistent microalbuminuria have markers of diffuse cardiac fibrosis.22

In a recent study S Sakthi Selva Kumar et al. has shown that there is a significant association between QTC
interval prolongation and microalbuminuria as evidenced by a greater number of cases with microalbuminuria having prolonged QTc interval.\textsuperscript{23}

The prevalence of CAN in diabetes mellitus is high. Higher age, longer duration of diabetes and peripheral neuropathy are significant risk factors.\textsuperscript{16} QTc interval in the ECG can be used to diagnose CAN with reasonable sensitivity, specificity and positive predictive value.\textsuperscript{16} The study suggests that QTc prolongation may be taken as a direct evidence of cardiac autonomic neuropathy in diabetics.\textsuperscript{24}

5. Conclusion

Although common among diabetic individuals, CAN is often under-recognised and undiagnosed cardiac complication. Though optimal management of DM from early stages of the disease can reduce the risk of diabetic heart disease. CAN is a common serious complication seen in Type-2 diabetic patient, it is associated with variety of adverse outcomes including cardiovascular deaths. Hence it is practically difficult to diagnose CAN in the clinics. Screening asymptomatic Type-2 diabetic patients for prolonged QTc is a simple objective of diagnosing CAN, with reasonable sensitivity, specificity and positive predictive value which can help us to monitor the patients more closely.

The lifetime risk seems to be invariably high in almost all patients with diabetes. The recent ESC guidelines considers that diabetes risk approaches the CHD risk when microalbuminuria is present.

Stratification of diabetic patients improves accuracy in prediction of subclinical CAD, silent ischemia and future cardiovascular events. Risk stratification is necessary to individualize treatment, and to reduce morbidity and mortality.

6. Source of Funding

None.

7. Conflict of Interest

The authors declare no conflict of interest.

References

1. International Diabetes Federation. IDF Diabetes Atlas, 9th edition (Online), 2019. Available from: https://www.diabetesatlas.org/en/.

2. Stumvoll M, Goldstein BJ, Haeften TV. Type 2 diabetes: Principles of pathogenesis and therapy. Lancet. 2005;365:1333–46.

3. Leiter LA. Beta cell preservation: A potential role for the thiazolidinediones to improve clinical care in type 2 diabetes. Diabet Med. 2005;22:963–72.

4. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020;21(17):6275.

5. Rajbhandari J, Fernandez C, Agarwal M, Yap BXY, Pappachan JM. Diabetic heart disease: A clinical update. World J Diabet. 2021;12(4):383–406. doi:10.4137/WJD.S124233.

6. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005–12.

7. Gunti S, Gruden G, Forneong P, Barutta F, Amiono C, Ghezzo G, et al. Increased QT interval dispersion predicts 15-year cardiovascular mortality in type 2 diabetic subjects: the population-based Casale Monferrato Study. Diabetes Care. 2012;35(3):581–3.

8. Rana BS, Lim PO, Naas AAO, Oxtson SA. QT interval abnormalities are often present at diagnosis in diabetes and are better predictors of cardiac death than ankle -brachial pressure index and autonomic function tests. Heart. 2005;91(1):44–50.

9. Naas AA, Davidson NC. QT and ETC dispersion are accurate predictors of cardiac death in newly diagnosed non-insulin dependent diabetes. Cohort study. BMJ. 1998;316:745–17.

10. Laitinen T, Vauhkonen I, Niskanen L, Hartikainen J, Uusitupa M, Laakso M. Prolonged corrected QT interval is associated with acute and chronic hyperinsulinemia in non diabetic subjects. Diabetes Care. 2003;26:2480–1. doi:10.2337/diacare.26.8.2480-a.

11. Rutter MK, Viswanath S, Mccomb JM, Marshall SM. QT prolongation in patients with type 2 diabetes and microalbuminuria. Olin Auton Res. 2002;12(5):366–72.

12. Matel D, Chiocchina AD, Stratone A. Utility of QTc interval for the diagnosis of cardiac autonomic neuropathy in type 2 diabetes mellitus. Rev Med Chir Soc Med Nat. 2010;114(1):282–6.

13. Bazetti HC. An analysis of the time relations of the electrocardiogram. Heart. 1920;7:353–57.

14. Kleg MJ, Whelton PK, Randall BL, Neaton JD, Stamler J. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA. 1997;277(16):1293–8.

15. Suarez GA, Clark VM, Norell JE, Kotte TE, Callahan MJ, O’Brien PC, et al. Sudden cardiac death in diabetes mellitus: risk factors in the Rochester diabetic neuropathy study. J Neurol Neurosurg Psychiatry. 2005;76(2):240–5. doi:10.1136/jnnp.2004.059570.

16. Pappachan JM, Sebastian J, Bino BC, Jayaprakash K, Vijayakumar K, Sujathan P, et al. Cardiac autonomic neuropathy in diabetes mellitus: prevalence, risk factors and utility of corrected QT interval in the ECG for its diagnosis. Postgrad Med J 2008;84(990):205–10.

17. Takebayashi K, Sugita R, Tayawa K, Aso Y, Takeyama Y, Inukai T. The connection between QT dispersion and autonomic neuropathy in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2003;111(6):351–7.

18. Porwal V, Raman PG. QT interval in diabetes mellitus. Int J Drab Dev Cities. 2005;25:46–9.

19. Vegilo M, Bruno G, Barra M. Prevalence of increased OT interval and other QT intervals in patients with type 2 diabetes. J Electrophysiol. 2007;91(1):44–50. doi:10.2337/diacare.26.8.2480-a.

20. Yeo CK, Nawawi HM, Kadir KA, Nazainimoon WMW. The comparison of QT dispersion and 24 hour ambulatory blood pressure monitoring amongst diabetic patients with and without microalbuminuria. Med J Malaysia. 2005;59:185–9.

21. Spallone V, Gambardelia S, Malello MR, Barini A, Frontoni S, Menzinger G. Relationship between autonomic neuropathy, 24-h blood pressure profile, and nephropathy in normotensive IDDM patients. Diabetes Care. 1994;17(6):578–84.

22. Swoboda PP, McDiamid AK, Ethayiemi B, Ripley DL, Ripley LE, Dobson P, et al. RESEARCH ARTICLE PDF/EPUB Tools Share Jump to Abstract Introduction Methods Results Discussion Conclusions Author Contributions Sources of Funding Disclosures Footnotes References Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure. J Am Heart Assoc. 2017;6(7):17.

23. Kumar SSS, Palaniandavan S, Padma V. Association Between Prolonged QTc Interval and Microalbuminuria in Patients of Type II
Author biography

Farzana Mustafa, Assistant Professor

Abdul Hai Mohammed, House Surgeon

Cite this article: Mustafa F, Mohammed AH. Study of QT interval prolongation in asymptomatic type-2 diabetes mellitus patients with and without microalbuminuria. Indian J Clin Anat Physiol 2021;8(3):235-240.